BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have received an average recommendation of “Moderate Buy” from the fourteen research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $385.0833.

Several brokerages recently commented on ONC. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, January 21st. Wall Street Zen lowered shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Barclays upped their price target on shares of BeOne Medicines from $394.00 to $405.00 and gave the stock an “overweight” rating in a research report on Friday, February 27th. Morgan Stanley reaffirmed an “overweight” rating and set a $405.00 price target on shares of BeOne Medicines in a research report on Thursday, January 8th. Finally, Guggenheim upped their price target on shares of BeOne Medicines from $400.00 to $410.00 and gave the stock a “buy” rating in a research report on Friday, February 27th.

Insider Buying and Selling

In related news, SVP Chan Henry Lee sold 1,660 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total transaction of $580,203.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.62% of the company’s stock.

Hedge Funds Weigh In On BeOne Medicines

Institutional investors and hedge funds have recently bought and sold shares of the stock. EFG International AG acquired a new stake in shares of BeOne Medicines in the fourth quarter worth $25,000. Anchor Investment Management LLC acquired a new stake in shares of BeOne Medicines in the second quarter worth $26,000. Leonteq Securities AG acquired a new stake in shares of BeOne Medicines in the fourth quarter worth $35,000. Daiwa Securities Group Inc. acquired a new stake in shares of BeOne Medicines in the second quarter worth $35,000. Finally, CWM LLC increased its position in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Stock Performance

NASDAQ:ONC opened at $312.19 on Thursday. The firm has a 50 day simple moving average of $318.19 and a 200-day simple moving average of $325.23. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.41 and a quick ratio of 3.08. The firm has a market cap of $34.25 billion, a PE ratio of 123.89 and a beta of 0.53. BeOne Medicines has a 1-year low of $196.45 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). The firm had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. BeOne Medicines had a net margin of 5.37% and a return on equity of 10.70%. On average, equities analysts expect that BeOne Medicines will post -5.82 EPS for the current year.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.